1-6 of 6
Ping Xu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors

Elizabeth A. Kuczynski, Janna Krueger, Annabelle Chow, Ping Xu, Shan Man, Yogi Sundaravadanam, Jessica K. Miller, Paul M. Krzyzanowski, Robert S. Kerbel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (4): 869–882.
https://doi.org/10.1158/1535-7163.MCT-17-1091
Published: 01 April 2018
View article titled, Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
Open the PDF for Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors in another window
Includes: Supplementary data
Journal Articles

Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Giulio Francia, Yuval Shaked, Kae Hashimoto, John Sun, Melissa Yin, Carolyn Cesta, Ping Xu, Shan Man, Christina Hackl, Julie Stewart, Mark Uhlik, Anne H. Dantzig, F. Stuart Foster, Robert S. Kerbel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (3): 680–689.
https://doi.org/10.1158/1535-7163.MCT-11-0659
Published: 06 March 2012
View article titled, Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
Open the PDF for Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis in another window
Includes: Multimedia, Supplementary data
Journal Articles

Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer

Kae Hashimoto, Shan Man, Ping Xu, William Cruz-Munoz, Terence Tang, Rakesh Kumar, Robert S. Kerbel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (4): 996–1006.
https://doi.org/10.1158/1535-7163.MCT-09-0960
Published: 07 April 2010
View article titled, Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer
Open the PDF for Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer in another window
Journal Articles

Abstract C49: Combination treatment with metronomic cyclophosphamide and the EGFR monoclonal antibody nimotuzumab is efficacious and non‐toxic in a preclinical model of advanced triple negative breast cancer

Anthony J. Mutsaers, Shan Man, Ping Xu, Ilia Tikhomirov, Robert S. Kerbel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C49.
https://doi.org/10.1158/1535-7163.TARG-09-C49
Published: 10 December 2009
View article titled, Abstract C49: Combination treatment with metronomic cyclophosphamide and the EGFR monoclonal antibody nimotuzumab is efficacious and non‐toxic in a preclinical model of advanced triple negative breast cancer
Journal Articles

Abstract A9: Potent preclinical impact of metronomic low‐dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

Kae Hashimoto, Shan Man, Ping Xu, William Cruz‐Munoz, Terence Tang, Anthony Mutsaers, Rakesh Kumar, Robert S. Kerbel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A9.
https://doi.org/10.1158/1535-7163.TARG-09-A9
Published: 10 December 2009
View article titled, Abstract A9: Potent preclinical impact of metronomic low‐dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer
Journal Articles

Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models

Laura G. Daenen, Yuval Shaked, Shan Man, Ping Xu, Emile E. Voest, Robert M. Hoffman, David J. Chaplin, Robert S. Kerbel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (10): 2872–2881.
https://doi.org/10.1158/1535-7163.MCT-09-0583
Published: 12 October 2009
View article titled, Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models
Open the PDF for Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models in another window